Rev. OFIL 2017, 27;3:235-240
Fecha de recepción: 08/11/2016 – Fecha de aceptación: 03/02/2017
Parro MA1, López S2, Sánchez M1, Chinea A2, Pueyo C1, Bermejo T1
1 Servicio de Farmacia
2 Servicio de Hematología
Hospital Universitario Ramón y Cajal. Madrid (España)
Mª Angeles Parro Martin
C/San Dacio, 15 – 5º Izda.
Correo electrónico: email@example.com
Objective: To evaluate the efficacy and safety of using foscarnet for the treatment of CMV infection in bone marrow transplant patients.
Method: Retrospective observational study in which all patients receiving foscarnet for the treatment of CMV viremia for one year were included. Were collected variables demographic, diagnostic, therapeutic, and laboratory. Efficacy was evaluated by negativization virus in blood and picture resolution of viremia. Toxicity hematological, renal, hepatic, metabolic and neurological was evaluated based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.
Results: 12 patients were evaluated with an average age of 45 years. Patients were mostly transplanted for acute myeloid leukemia and acute lymphoblastic leukemia. 8 patients received prior treatment for CMV viremia with intravenous ganciclovir and valganciclovir or 4 patients with oral acyclovir. 16.6% of patients not negativized the virus, the rest became negative with an average of 18.5 days. 41.7% had renal toxicity, hepatic toxicity 58.4%, 41.7% experienced a worsening of hematologic toxicity and all had metabolic toxicity.
Conclusions: Foscarnet has proven effective in the treatment of CMV infection in bone marrow transplant patients. The toxicity caused by the drug is less than expected, especially renal and hematological level.
Key Words: Foscarnet, cytomegalovirus, bone marrow transplant, security, effectiveness.